Mesenchymal
stem cell (MSCs) therapy has recently received profound
interest as a targeting platform in cancer theranostics because of
inherent tumor-homing abilities. However, the terminal tracking of
MSCs engraftment by fluorescent in situ hybridization, immuno-histochemistry,
and flow-cytometry techniques to translate into clinics is still challenging
because of a dearth of inherent MSCs-specific markers and FDA approval
for genetic modifications of MSCs. To address this challenge, a cost-effective
noninvasive imaging technology based on multifunctional nanocrystals
(NCs) with enhanced detection sensitivity, spatial–temporal
resolution, and deep-tissue diagnosis is needed to be developed to
track the transplanted stem cells. A hassle-free labeling of human
umbilical cord Wharton’s Jelly (WJ)-derived MSCs with Mn2+ and Gd3+ co-doped CuInS2−ZnS
(CIS-ZMGS) NCs has been demonstrated in 2 h without requiring an electroporation
process or transfection agents. It has been found that WJ-MSCs labeling
did not affect their multilineage differentiation (adipocyte, osteocyte,
chondrocyte), immuno-phenotypes (CD44+, CD105+, CD90+), protein (β-actin, vimentin, CD73, α-SMCA),
and gene expressions. Interestingly, CIS-ZMGS-NCs-labeled WJ-MSCs
exhibit near-infrared (NIR) fluorescence with a quantum yield of 84%,
radiant intensity of ∼3.999 × 1011 (p/s/cm2/sr)/(μW/cm2), magnetic relaxivity (longitudinal r
1 = 2.26 mM–1 s–1, transverse r
2 = 16.47 mM–1 s–1), and X-ray attenuation (78 HU) potential
for early noninvasive multimodality imaging of a subcutaneous melanoma
in B16F10-tumor-bearing C57BL/6 mice in 6 h. The ex vivo imaging and
inductively coupled plasma mass-spectroscopy analyses of excised organs
along with confocal microscopy and immunofluorescence of tumor results
also significantly confirmed the positive tropism of CIS-ZMGS-NCs-labeled
WJ-MSCs in the tumor environment. Hence, we propose the magnetofluorescent
CIS-ZMGS-NCs-labeled WJ-MSCs as a next-generation nanobioprobe of
three commonly used imaging modalities for stem cell-assisted anticancer
therapy and tracking tissue/organ regenerations.